PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance

M Rose, JT Burgess, K O'Byrne, DJ Richard… - Frontiers in cell and …, 2020 - frontiersin.org
The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular
processes, including the regulation of transcription, apoptosis and the DNA damage …

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

GE Konecny, RS Kristeleit - British journal of cancer, 2016 - nature.com
Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death
in homologous recombination (HR)-deficient cancers, including BRCA-mutated tumours, by …

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency

K Cong, M Peng, AN Kousholt, WTC Lee, S Lee… - Molecular cell, 2021 - cell.com
Mutations in BRCA1 or BRCA2 (BRCA) is synthetic lethal with poly (ADP-ribose)
polymerase inhibitors (PARPi). Lethality is thought to derive from DNA double-stranded …

XRCC1 prevents toxic PARP1 trapping during DNA base excision repair

AA Demin, K Hirota, M Tsuda, M Adamowicz… - Molecular cell, 2021 - cell.com
Mammalian DNA base excision repair (BER) is accelerated by poly (ADP-ribose)
polymerases (PARPs) and the scaffold protein XRCC1. PARPs are sensors that detect …

Eukaryotic base excision repair: new approaches shine light on mechanism

WA Beard, JK Horton, R Prasad… - Annual review of …, 2019 - annualreviews.org
Genomic DNA is susceptible to endogenous and environmental stresses that modify DNA
structure and its coding potential. Correspondingly, cells have evolved intricate DNA repair …

Immediate-early, early, and late responses to DNA double stranded breaks

SR Kieffer, NF Lowndes - Frontiers in Genetics, 2022 - frontiersin.org
Loss or rearrangement of genetic information can result from incorrect responses to DNA
double strand breaks (DSBs). The cellular responses to DSBs encompass a range of highly …

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

B Pellegrino, A Herencia-Ropero, A Llop-Guevara… - Cancer research, 2022 - AACR
PARP inhibitors (PARPi) are approved drugs for platinum-sensitive, high-grade serous
ovarian cancer (HGSOC) and for breast, prostate, and pancreatic cancers (PaC) harboring …

[HTML][HTML] DNA repair mechanisms and their clinical impact in glioblastoma

H Erasimus, M Gobin, S Niclou, E Van Dyck - Mutation Research/Reviews …, 2016 - Elsevier
Despite surgical resection and genotoxic treatment with ionizing radiation and the DNA
alkylating agent temozolomide, glioblastoma remains one of the most lethal cancers, due in …

PARP inhibitors in ovarian cancer

G Mittica, E Ghisoni, G Giannone… - Recent patents on …, 2018 - ingentaconnect.com
Background: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery
and platinum doublet chemotherapy, is associated with high risk of relapse and poor …

Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand

PS Patel, A Algouneh, R Hakem - Oncogene, 2021 - nature.com
The principle of synthetic lethality, which refers to the loss of viability resulting from the
disruption of two genes, which, individually, do not cause lethality, has become an attractive …